Back to User profile » Professor Alberto Papi

Papers published by Professor Alberto Papi:


Risk of Pneumonia in Patients with COPD Initiating Fixed Dose Inhaled Corticosteroid (ICS) / Long-Acting Bronchodilator (LABD) Formulations Containing Extrafine Beclometasone Dipropionate versus Patients Initiating LABD Without ICS

Price D, Henley W, Cançado JED, Fabbri LM, Kerstjens HA, Papi A, Roche N, Şen E, Singh D, Vogelmeier CF, Nudo E, Carter V, Skinner D, Vella R, Soriano JB, Kots M, Georges G

Pragmatic and Observational Research 2024, 15:1-16

Published Date: 20 January 2024

A Long-Term Study of Adverse Outcomes Associated With Oral Corticosteroid Use in COPD

Tse G, Emmanuel B, Ariti C, Bafadhel M, Papi A, Carter V, Zhou J, Skinner D, Xu X, Müllerová H, Price D

International Journal of Chronic Obstructive Pulmonary Disease 2023, 18:2565-2580

Published Date: 15 November 2023

Symptom Burden, Health Status, and Productivity in Patients with Uncontrolled and Controlled Severe Asthma in NOVELTY

Ding B, Chen S, Srivastava D, Quinton A, Cook W, Papi A, Reddel HK

Journal of Asthma and Allergy 2023, 16:611-624

Published Date: 11 June 2023

The Effect of Maintenance Treatment with Erdosteine on Exacerbation Treatment and Health Status in Patients with COPD: A Post-Hoc Analysis of the RESTORE Dataset

Calverley PMA, Papi A, Page C, Rogliani P, Dal Negro RW, Cazzola M, Cicero AF, Wedzicha JA

International Journal of Chronic Obstructive Pulmonary Disease 2022, 17:1909-1920

Published Date: 22 August 2022

Interclass Difference in Pneumonia Risk in COPD Patients Initiating Fixed Dose Inhaled Treatment Containing Extrafine Particle Beclometasone versus Fine Particle Fluticasone [Corrigendum]

Price DB, Henley W, Cançado JED, Fabbri LM, Kerstjens HA, Papi A, Roche N, Şen E, Singh D, Vogelmeier CF, Barille S, Nudo E, Carter V, Skinner D, Vella R, Georges G

International Journal of Chronic Obstructive Pulmonary Disease 2022, 17:489-490

Published Date: 7 March 2022

Interclass Difference in Pneumonia Risk in COPD Patients Initiating Fixed Dose Inhaled Treatment Containing Extrafine Particle Beclometasone versus Fine Particle Fluticasone

Price DB, Henley W, Cançado JED, Fabbri LM, Kerstjens HA, Papi A, Roche N, Şen E, Singh D, Vogelmeier CF, Barille S, Nudo E, Carter V, Skinner D, Vella R, Georges G

International Journal of Chronic Obstructive Pulmonary Disease 2022, 17:355-370

Published Date: 15 February 2022

Burden of Pertussis in Individuals with a Diagnosis of Asthma: A Retrospective Database Study in England

Bhavsar A, Aris E, Harrington L, Simeone JC, Ramond A, Lambrelli D, Papi A, Boulet LP, Meszaros K, Jamet N, Sergerie Y, Mukherjee P

Journal of Asthma and Allergy 2022, 15:35-51

Published Date: 11 January 2022

Real-World Experience with Dupilumab in Severe Asthma: One-Year Data from an Italian Named Patient Program

Campisi R, Crimi C, Nolasco S, Beghè B, Antonicelli L, Guarnieri G, Scichilone N, Porto M, Macchia L, Scioscia G, Foschino Barbaro MP, Papi A, Crimi N

Journal of Asthma and Allergy 2021, 14:575-583

Published Date: 27 May 2021

Dupilumab Efficacy in Patients Stratified by Baseline Treatment Intensity and Lung Function

Pavord ID, Siddiqui S, Papi A, Corren J, Sher LD, Bardin P, Langton D, Park HS, Rice MS, Deniz Y, Rowe P, Staudinger HW, Patel N, Ruddy M, Graham NMH, Teper A

Journal of Asthma and Allergy 2020, 13:701-711

Published Date: 16 December 2020

A Comparison of the Real-Life Clinical Effectiveness of the Leading Licensed ICS/LABA Combination Inhalers in the Treatment for COPD

Ming SWY, Haughney J, Ryan D, Small I, Lavorini F, Papi A, Singh D, Halpin DMG, Hurst JR, Patel S, Ochel M, Kocks J, Carter V, Hardjojo A, Price DB

International Journal of Chronic Obstructive Pulmonary Disease 2020, 15:3093-3103

Published Date: 26 November 2020

The Burden of Self-Reported Rhinitis and Associated Risk for Exacerbations with Moderate-Severe Asthma in Primary Care Patients

Kritikos V, Price D, Papi A, Infantino A, Ställberg B, Ryan D, Lavorini F, Chrystyn H, Haughney J, Lisspers K, Gruffydd-Jones K, Román Rodríguez M, Høegh Henrichsen S, van der Molen T, Carter V, Bosnic-Anticevich S

Journal of Asthma and Allergy 2020, 13:415-428

Published Date: 6 October 2020

Extrafine triple therapy delays COPD clinically important deterioration vs ICS/LABA, LAMA, or LABA/LAMA

Singh D, Fabbri LM, Vezzoli S, Petruzzelli S, Papi A

International Journal of Chronic Obstructive Pulmonary Disease 2019, 14:531-546

Published Date: 28 February 2019

Triple therapy (ICS/LABA/LAMA) in COPD: time for a reappraisal

Vanfleteren L, Fabbri LM, Papi A, Petruzzelli S, Celli B

International Journal of Chronic Obstructive Pulmonary Disease 2018, 13:3971-3981

Published Date: 12 December 2018

Fluticasone propionate/formoterol for COPD management: a randomized controlled trial

Papi A, Dokic D, Tzimas W, Mészáros I, Olech-Cudzik A, Koroknai Z, McAulay K, Mersmann S, Dalvi PS, Overend T

International Journal of Chronic Obstructive Pulmonary Disease 2017, 12:1961-1971

Published Date: 5 July 2017